Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS builds senior staff

Executive Summary

HHS Deputy Assistant Secretary for Public Health Emergency Preparedness William Raub will serve as Acting Counselor for Science Policy. Raub will be a senior policy advisor to Secretary Michael Leavitt, with responsibilities including FDA issues. He formerly sat on HHS' drug importation task force, which said the practice would be costly, risky and harmful to innovation (1"The Pink Sheet" Jan. 3, 2005, p. 28). Assistant Secretary for Legislation Jennifer Young will serve as Acting Senior Counselor for Health Policy, a new position. Young will advise Leavitt on health care issues including Medicare and Medicaid...

You may also be interested in...



Canada-Only Import Plan “Feasible,” HHS Says: Savings Would Be “Modest”

The Bush Administration would accept a Canada-only importation program that focuses solely on high volume brands, HHS Secretary Thompson and Commerce Secretary Donald Evans indicated in a Dec. 21 letter to Congress

Setback For Athenex, Hanmi As CRL Requests New Trial

Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.

Chordia Looks To Forge Own Path In Oncology

Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel